Compare Salesforce Inc (CRM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs GeneDx Holdings Corp — how do they compare? Salesforce Inc trades at $168 (market cap $137.23B), while GeneDx Holdings Corp trades at $63.32 (market cap $1.85B). The key difference: Salesforce Inc is far larger — about 74.2× GeneDx Holdings Corp's market cap, and Salesforce Inc pays a 1.05% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| CRM | WGS | |
|---|---|---|
Market Cap | $137.23B | $1.85B |
Sector | Technology | Technology |
52-Week High | $270.25 | $167.51 |
52-Week Low | $150.12 | $34.51 |
Enterprise Value | $167.28B | $1.85B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $168.75, down 1.44% on the day amid a broader tech sell-off. The stock exhibits a neutral technical signal with support near $165 and resistance at $171. Fundamentally, the company shows strong profitability with a 77.64% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights AI-driven growth potential but also reflects market concerns over software stock volatility.
The outlook remains positive given robust earnings beats, high analyst buy ratings (76.84%), and a consensus price target of $235.90, implying significant upside. Key risks include competitive pressures in AI, macroeconomic sensitivity, and the stock's high valuation multiples. Revenue growth and AI monetization are critical catalysts for future performance.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
